dc.relation.reference | 1. Pfleiderer, A. Diagnosis and staging of ovarian cancer. J Cancer Res Clin Oncol, 107: 81-88, 1984.
2. Gonzalez-Diego, P., Lopez-Abente, G., Pollan, M., and Ruiz, M. Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer, 36: 1816-1824, 2000.
3. Tarone, R. E. and Chu, K. C. Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat, 5: 221-231, 2000.
4. Parkin, D. M., Pisani, P., and Ferlay, J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer, 54: 594-606, 1993.
5. Beard, C. M., Hartmann, L. C., Atkinson, E. J., O'Brien, P. C., Malkasian, G. D., Keeney, G. L., and Melton, L. J., 3rd The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol, 10: 14-23, 2000.
6. Boyle, P., Maisonneuve, P., and Autier, P. Update on cancer control in women. Int J Gynaecol Obstet, 70: 263-303, 2000.
7. Gonzalez-Diego, P., Lopez-Abente, G., Pollan, M., and Ruiz, M. Time trends in ovarian cancer mortality in europe (1955-1993). effect Of age, birth cohort and period of death [In Process Citation]. Eur J Cancer, 36: 1816-1824, 2000.
8. Rustin, G. J. Tumour markers for ovarian cancer. Eur J Cancer, 28: 2-3, 1992.
9. Sorbe, B., Frankendal, B., and Veress, B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol, 59: 576-582, 1982.
10. Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., and Elashoff, R. M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol, 61: 413-420, 1983.
11. Malkasian, G. D., Jr., Melton, L. J., 3rd, O'Brien, P. C., and Greene, M. H. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol, 149: 274-284, 1984.
12. Swenerton, K. D., Hislop, T. G., Spinelli, J., LeRiche, J. C., Yang, N., and Boyes, D. A. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol, 65: 264-270, 1985.
13. Jacobs, I. and Bast, R. C., Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod, 4: 1-12, 1989.
14. Mazurek, A., Niklinski, J., Laudanski, T., and Pluygers, E. Clinical tumour markers in ovarian cancer. Eur J Cancer Prev, 7: 23-35, 1998.
15. Berek, J. S. and Bast, R. C., Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 76: 2092-2096, 1995.
16. Guadagni, F., Roselli, M., Cosimelli, M., Ferroni, P., Spila, A., Cavaliere, F., Casaldi, V., Wappner, G., Abbolito, M. R., Greiner, J. W., and et al. CA 72-4 serum marker--a new tool in the management of carcinoma patients. Cancer Invest, 13: 227-238, 1995.
17. Pannek, J. and Partin, A. W. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. Semin Urol Oncol, 16: 100-105, 1998.
18. Hunerbein, M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res, 146: 48-55, 1998.
19. Posner, M. R. and Mayer, R. J. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am, 8: 533-553, 1994.
20. Rubach, M., Szymendera, J. J., Kaminska, J., and Kowalska, M. Serum CA 15.3, CEA and ESR patterns in breast cancer. Int J Biol Markers, 12: 168-173, 1997.
21. Chang, K. and Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A, 93: 136-140, 1996.
22. Yamaguchi, N., Hattori, K., Oh-eda, M., Kojima, T., Imai, N., and Ochi, N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem, 269: 805-808, 1994.
23. Chang, K., Pastan, I., and Willingham, M. C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer, 50: 373-381, 1992.
24. Hough, C. D., Sherman-Baust, C. A., Pizer, E. S., Montz, F. J., Im, D. D., Rosenshein, N. B., Cho, K. R., Riggins, G. J., and Morin, P. J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res, 60: 6281-6287, 2000.
25. Sobin LH, W. C. UICC TNM Classification of Malignant Tumors, 5th ed. New York, New York: Wiley iss, 1997.
26. Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G. E., Hellstrom, K. E., and Hellstrom, I. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A, 96: 11531-11536, 1999.
27. Cheng, W. F., Hung, C. F., Chai, C. Y., Hsu, K. F., He, L., Rice, C. M., Ling, M., and Wu, T. C. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol, 166: 6218-6226, 2001.
28. Bera, T. K. and Pastan, I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol, 20: 2902-2906, 2000.
29. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4: 844-847, 1998.
30. Mok, S. C., Chao, J., Skates, S., Wong, K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., and Cramer, D. W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst, 93: 1458-1464, 2001.
31. Wang, K., Gan, L., Jeffery, E., Gayle, M., Gown, A. M., Skelly, M., Nelson, P. S., Ng, W. V., Schummer, M., Hood, L., and Mulligan, J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene, 229: 101-108, 1999.
32. Bast, R. C., Jr., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., and Knapp, R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 68: 1331-1337, 1981.
33. Bast, R. C., Jr., Klug, T. L., St John, E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., Zurawski, V. R., Jr., and Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309: 883-887, 1983.
34. Meyer, T. and Rustin, G. J. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer, 82: 1535-1538, 2000.
35. Chen, C. A., Cheng, W. F., Lee, C. N., Chen, T. M., Kung, C. C., Hsieh, F. J., and Hsieh, C. Y. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol, 74: 235-240, 1999.
36. Tuxen, M. K., Soletormos, G., and Dombernowsky, P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev, 21: 215-245, 1995.
37. Mills, G. B., Bast, R. C., Jr., and Srivastava, S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst, 93: 1437-1439, 2001.
38. Robertson, D. M., Stephenson, T., Pruysers, E., Burger, H. G., McCloud, P., Tsigos, A., Groome, N., Mamers, P., McNeilage, J., Jobling, T., and Healy, D. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol, 191: 97-103, 2002.
39. Gadducci, A., Zola, P., Landoni, F., Maggino, T., Sartori, E., Bergamino, T., and Cristofani, R. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol, 58: 42-47, 1995.
40. Tate, S., Hirai, Y., Takeshima, N., and Hasumi, K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol, 96: 143-149, 2005.
41. Hassan, R., Viner, J. L., Wang, Q. C., Margulies, I., Kreitman, R. J., and Pastan, I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother, 23: 473-479, 2000.
42. Hassan, R., Lerner, M. R., Benbrook, D., Lightfoot, S. A., Brackett, D. J., Wang, Q. C., and Pastan, I. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res, 8: 3520-3526, 2002.
43. Sato, N., Fukushima, N., Maitra, A., Iacobuzio-Donahue, C. A., van Heek, N. T., Cameron, J. L., Yeo, C. J., Hruban, R. H., and Goggins, M. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol, 164: 903-914, 2004.
44. Iacobuzio-Donahue, C. A., Ashfaq, R., Maitra, A., Adsay, N. V., Shen-Ong, G. L., Berg, K., Hollingsworth, M. A., Cameron, J. L., Yeo, C. J., Kern, S. E., Goggins, M., and Hruban, R. H. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res, 63: 8614-8622, 2003.
45. Ryu, B., Jones, J., Blades, N. J., Parmigiani, G., Hollingsworth, M. A., Hruban, R. H., and Kern, S. E. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res, 62: 819-826, 2002.
46. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E., Yeo, C. J., Cameron, J. L., Kern, S. E., and Hruban, R. H. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res, 7: 3862-3868, 2001.
47. Swierczynski, S. L., Maitra, A., Abraham, S. C., Iacobuzio-Donahue, C. A., Ashfaq, R., Cameron, J. L., Schulick, R. D., Yeo, C. J., Rahman, A., Hinkle, D. A., Hruban, R. H., and Argani, P. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol, 35: 357-366, 2004.
48. Antonescu, C. R., Viale, A., Sarran, L., Tschernyavsky, S. J., Gonen, M., Segal, N. H., Maki, R. G., Socci, N. D., DeMatteo, R. P., and Besmer, P. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res, 10: 3282-3290, 2004.
49. Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E., and Hellstrom, I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet, 362: 1612-1616, 2003.
50. Frierson, H. F., Jr., Moskaluk, C. A., Powell, S. M., Zhang, H., Cerilli, L. A., Stoler, M. H., Cathro, H., and Hampton, G. M. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol, 34: 605-609, 2003. | en |